Everything below concerns lyophilized powder. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-06-05. Where a claim depends on a specific study, the study is described rather than over-claimed.
The compound emerged from work at a Canadian biotechnology firm in the early 2000s. Early human studies examined its effect on growth hormone and insulin-like growth factor 1 in healthy volunteers and in people with HIV-associated fat redistribution. Reports described sustained increases in both markers after a single injection. Development did not advance to regulatory approval, and the clinical programme was later discontinued. The molecule is now encountered mainly as a research chemical rather than a marketed medicine.
Two forms circulate in research settings and are frequently confused. One carries the drug affinity complex and is often written as CJC-1295 with DAC; the other lacks that group and is usually called modified GRF(1-29). The two share the same core sequence but differ sharply in how long they persist in blood. Products labelled only as CJC-1295 normally refer to the version carrying the complex. Documentation that omits the distinction leaves the intended molecule ambiguous.
CJC-1295 is a synthetic peptide built as a long-acting analogue of growth hormone-releasing hormone. Its backbone matches the first twenty-nine residues of the natural human hormone, with four amino acid substitutions added to slow enzymatic breakdown. A reactive maleimide group, commonly termed the drug affinity complex, allows the peptide to attach to circulating albumin after administration. That albumin attachment keeps the molecule in the bloodstream for an extended period instead of being cleared within minutes.
CJC-1295 is a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. Its sequence corresponds to the first twenty-nine residues of human GHRH, with four substitutions that slow enzymatic breakdown. Early descriptions placed the compound in research on growth hormone deficiency and related conditions, and later literature groups it with the long-acting GHRH analogs. The name appears in both laboratory and popular fitness writing, where it sometimes labels chemically different peptides.
Two related peptides circulate under the CJC-1295 label, and they differ mainly in how long they persist in circulation. The version carrying a drug affinity complex includes a maleimidopropionic acid linker that forms a covalent bond with serum albumin. The other version, usually written as modified GRF(1-29) or tetrasubstituted GRF(1-29), lacks that linker and is cleared quickly. Mixing the two produces inconsistent readings of published half-life values, because the linker rather than the receptor-facing sequence drives most of the difference.
The core sequence keeps the receptor-binding region of GHRH while replacing four positions that are vulnerable to dipeptidyl peptidase-4 and other proteases. Substitutions at positions 2, 8, 15, and 27 raise metabolic stability relative to the natural hormone. The N-terminal residues remain essential for activity, so changes there generally lower potency. Molecular weight sits near 3368 daltons for the tetrasubstituted analog without the linker, while the albumin-binding form is heavier because of the added maleimide group.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C152H252N44O42 | Cited for the form without the drug affinity complex |
| Molecular weight | About 3368 Da | Reported value for modified GRF(1-29) |
| Appearance | White to off-white powder | Lyophilised solid as usually supplied |
| Solubility | Soluble in water and polar solvents | Clarity depends on purity and salt content |
| Typical storage | -20 C or below, dry | Protect from light and repeated warming cycles |
The peptide binds GHRH receptors on somatotroph cells within the anterior pituitary, triggering a signalling cascade that increases growth hormone secretion. Its improved resistance to dipeptidyl peptidase IV degradation distinguishes it from the parent hormone. In the DAC-bearing version, a maleimide group reacts with a cysteine residue on serum albumin, forming a covalent bond that keeps the peptide in circulation far longer. That albumin attachment is the central design feature separating the two research variants.
Pharmacokinetic behaviour differs sharply between the two forms. The DAC-bearing peptide shows an extended circulation time measured in days, whereas the version without the complex is cleared within roughly half an hour. This gap shapes how researchers design dosing schedules in animal models. Whether the prolonged presence of the DAC form produces effects meaningfully different from the short-acting variant remains an open question, since comparative human data are scarce.
CJC-1295 is a synthetic peptide designed to mimic growth hormone-releasing hormone (GHRH), the endogenous signal that prompts the pituitary gland to release growth hormone. The compound is a modified fragment of the natural hormone, spanning the first twenty-nine amino acids of GHRH with several substitutions that slow enzymatic breakdown. Two variants circulate in research settings: one carrying a drug affinity complex (DAC) and one without it. The DAC-free form is frequently labelled Mod GRF(1-29) in catalogs and discussion forums.
The two variants differ dramatically in how long they persist in circulation. The form lacking the albumin-binding group has a plasma half-life measured in tens of minutes, comparable to the natural hormone fragment. The version carrying the drug affinity complex binds albumin and shows a half-life of roughly six to eight days in human studies. That figure comes from small trials that tracked hormone levels over extended periods. The physiological consequences of sustained versus pulsatile stimulation are still debated and the literature does not settle the point.
Lyophilized peptide powder is comparatively stable when kept dry, cold, and protected from light. Once dissolved, the molecule is vulnerable to deamidation, oxidation, and aggregation, with the rate depending on pH, buffer composition, and temperature. Alkaline conditions and repeated freeze-thaw cycles accelerate loss of the intact peptide. The methionine present in the native sequence is a known oxidation site, which is one reason it was replaced in the modified fragment. Suppliers typically recommend cold storage of solutions and use within a short window.
Analytical confirmation usually relies on reversed-phase high-performance liquid chromatography for purity and on liquid chromatography coupled to mass spectrometry for identity. Mass data reveal the expected molecular mass and can flag truncated or oxidized species. Amino acid analysis and peptide mapping provide sequence-level verification. Immunoassays are used in some biological matrices, but antibodies raised against one releasing-hormone analog may cross-react with another. Reported purity figures depend heavily on the method used, so comparisons between suppliers require matching the analytical approach.
Lyophilized material is typically stored at minus twenty degrees Celsius or lower. Keeping the vial dry and protected from light preserves peptide integrity. Repeated freeze-thaw cycles can cause aggregation or loss of activity. Once dissolved, solutions are generally kept at two to eight degrees Celsius. Stability data for reconstituted solutions vary, and long-term behavior is not fully established. Working aliquots reduce the number of times a stock container is opened.
Reverse-phase high-performance liquid chromatography is the standard tool for purity assessment. The technique separates the target peptide from truncated or modified byproducts. Mass spectrometry confirms molecular weight and supports sequence verification. Electrospray ionization and matrix-assisted laser desorption are both used. Amino acid analysis provides an independent check on composition. Purity values are commonly reported as area percentage from the chromatogram. Residual trifluoroacetate and water content are also measured in many quality programs.
Batch-to-batch consistency depends on solid-phase peptide synthesis and subsequent purification. Coupling efficiency, resin choice, and cleavage conditions all affect the final profile. Counter-ion content and moisture can shift the apparent mass of a batch. Documentation typically includes a certificate of analysis with chromatograms and spectra. Independent verification by a second laboratory is sometimes requested. Whether a given certificate reflects the actual vial contents depends on chain of custody. Analytical methods themselves carry uncertainty that should be stated alongside results.
==== International law ==== Law professor Mary Ellen O'Connell said that the strike "violated fundamental principles of international law". Luke Moffett of Queen's University Belfast, also a law professor, stated that striking the ship without grounds of self-defense could be extrajudicial killing. In October, the Associated Press stated that the Trump administration is "treating alleged drug traffickers as unlawful combatants who must be met with military force". Regarding the 2 September strike, Geoffrey Corn, former senior adviser on the law of war to the US Army, said "I don't think there is any way to legitimately characterize a drug ship heading from Venezuela, arguably to Trinidad, as an actual or imminent armed attack against the United States, justifying this military response." George W. Bush administration legal figure John Yoo has also questioned the legality of the strikes arguing that "There has to be a line between crime and war." Obama era legal figure Harold Hongju Koh said that the strikes were "lawless, dangerous and reckless". Former chief White House ethics lawyer Richard Painter called the strikes a violation of international and federal law. Unnamed sources told The New York Times and the Washington Post that the US military used a plane during the first strike in September 2025 that was part of a US Air Force fleet painted to look like civilian aircraft.
== Classification == The classification of dinosaur eggs is based on the structure of the egg shells viewed in thin section via microscope, although new techniques such as electron backscatter diffraction have been used. There are three main categories of dinosaur eggs: spherulitic (sauropods and hadrosaurs), prismatic, and ornithoid (theropods, including modern birds).
== Pipeline drugs == Lucitanib is a tyrosine kinase activity inhibitor, highly selective for VEGFR types 1-3, FGFR types 1-2 and PDGFR alpha/beta. Tumor types such as breast carcinoma show amplification of fibroblast growth factor related genes. Simultaneous inhibition of VEGF and FGF receptors in FGFR1 dependent tumors could be therapeutically advantageous. Lucitanib has been shown to have promising efficacy, a manageable side-effect profile and clinical benefits in both FGF-aberrant and angiogenesis-sensitive populations leading to a phase II program being planned. Motesanib is a small-molecule multikinase inhibitor highly selective for VEGFR 1-3, PDGFR and KIT. The drug has shown anti-tumor activity as a monotherapy in advanced solid tumors. Vatalanib is an antiangiogenic VEGFR inhibiting molecule which is being researched as a potential treatment of solid tumors. Vatalanib inhibits VEGFR 1-4 although it has greater potency as an inhibitor of VEGFR 1-2. At concentrations under 10 μM, Vatalanib does not have cytotoxic or antiproliferative effects on cells that do not express VEGF. Specific inhibition of tumor-induced angiogenesis like the inhibition by Vatalanib can both prevent ongoing growth of tumors and the metastatic potential. Cediranib is a multi VEGFR 1-3 inhibitor being tested as a maintenance treatment for patients with platinum sensitive relapsed ovarian cancer. Cediranib stops blood flow to the site of the tumour and thereby inhibits its growth.
Sources: en.wikipedia.org
== Research == AAS, alone and in combination with progestogens, have been studied as potential male hormonal contraceptives. Dual AAS and progestins such as trestolone and dimethandrolone undecanoate have also been studied as male contraceptives, with the latter under active investigation as of 2018. Topical androgens have been used and studied in the treatment of cellulite in women. Topical androstanolone on the abdomen has been found to significantly decrease subcutaneous abdominal fat in women, and hence may be useful for improving body silhouette. However, men and hyperandrogenic women have higher amounts of abdominal fat than healthy women, and androgens have been found to increase abdominal fat in postmenopausal women and transgender men as well.
== Selected publications == Robinson, Arthur B.; McKerrow, James H.; Cary, Paul (1970). "Controlled Deamidation of Peptides and Proteins: An Experimental Hazard and a Possible Biological Timer". PNAS. 66 (3): 753–757. Bibcode:1970PNAS...66..753R. doi:10.1073/pnas.66.3.753. PMC 283114. PMID 5269237. Pauling, Linus; Robinson, Arthur B.; Teranishi, Roy; Cary, Paul (1971). "Quantitative Analysis of Urine Vapor and Breath by Gas-Liquid Partition Chromatography". PNAS. 68 (10): 2374–2376. Bibcode:1971PNAS...68.2374P. doi:10.1073/pnas.68.10.2374. PMC 426616. PMID 5289873. Robinson, Arthur B.; Robinson, Laurelee R. (1991). "Distribution of glutamine and asparagine residues and their near neighbors in peptides and proteins". PNAS. 88 (20): 8880–8884. Bibcode:1991PNAS...88.8880R. doi:10.1073/pnas.88.20.8880. PMC 52614. PMID 1924347. Soon, Willie H.; Baliunas, Sallie L.; Robinson, Arthur B.; Robinson, Zachary W. (1999). "Environmental effects of increased atmospheric carbon dioxide". Climate Research. 13 (2): 149–164. Bibcode:1999ClRes..13..149S. doi:10.3354/cr013149. Robinson, Noah E.; Robinson, Arthur B. (2001). "Molecular clocks". PNAS. 98 (3): 944–949. Bibcode:2001PNAS...98..944R. doi:10.1073/pnas.98.3.944. PMC 14689. PMID 11158575. Robinson, Arthur B.; Robinson, Noah E. (2008). "Use of Merrifield solid phase peptide synthesis in investigations of biological deamidation of peptides and proteins". Peptide Science. 90 (3): 297–306. doi:10.1002/bip.20852. PMID 17896348. S2CID 35618789.
==== 11beta-hydroxysteroid dehydrogenases ==== Cortisol is metabolized reversibly to cortisone by the 11-beta hydroxysteroid dehydrogenase system (11-beta HSD), which consists of two enzymes: 11-beta HSD1 and 11-beta HSD2. The metabolism of cortisol to cortisone involves oxidation of the hydroxyl group at the 11-beta position.
Benzodiazepines have robust efficacy in the short-term management of generalized anxiety disorder (GAD) when standardized measures of anxiety are used as the outcome variable, but did not demonstrate a favorable dropout rate compared to placebo in one meta-analysis. A newer meta-analysis showed that benzodiazepines are significantly more effective than serotonergic agents, regardless of treatment length. More research is needed, but unfortunately, newer randomized controlled trials are scarce for the off patent benzodiazepines. According to National Institute for Health and Clinical Excellence (NICE), benzodiazepines can be used in the immediate management of GAD, if necessary. However, they should not usually be given for longer than 2–4 weeks. The only medications NICE recommends for the longer-term management of GAD are antidepressants. Likewise, the Canadian Psychiatric Association (CPA) recommends benzodiazepines alprazolam, bromazepam, lorazepam, and diazepam only as a second-line choice, if the treatment with two different antidepressants was unsuccessful. Although they are second-line agents, benzodiazepines can be used for a limited time to relieve severe anxiety and agitation. CPA guidelines state that after 4–6 weeks the effect of benzodiazepines may decrease to the level of placebo, and that benzodiazepines are less effective than antidepressants in alleviating ruminative worry, the core symptom of GAD, but that in some cases, a prolonged treatment with benzodiazepines as the add-on to an antidepressant may be justified.
Sources: en.wikipedia.org
The ruling classes and "owners" of Ecuador worked to generate awareness in the masses about the act of aggression for which it fell equally on the government and on the people; what would be in the words of Cairo: "territorialist indoctrination of populations", based on borders that did not respond to legal reality. During the 1950s, this preaching would be reinforced and thus became a State policy that, in a certain way, unified the consciences and the national soul of Ecuadorians in an anti-Peruvian feeling for an imaginary territorial integrity. Ecuador and its people only had to take refuge in a doubtful border line of an equally doubtful Pedemonte-Mosquera Protocol of 1829. This negative awareness was included in basic education textbooks, reaching the point of locating its roots in the clash between Huáscar and Atahualpa, justification for which anti-Peruvianism acquired a historical rationality. In accordance with the above, the hegemonic meaning of national construction in Ecuador has been permanently related to the obsession with territorial integrity derived from the wars with the Peru. Anti-Peruvianism, expression of the existence of the other, would be an essential component element of what some have called "Ecuadorianness", generating biased interpretations about the times of the expansion of the Inca Empire, currently considered, like Spain.
=== Stool analysis (stool sample) === Clinical laboratory examination of feces, usually termed as stool examination or stool test, is conducted for the sake of diagnosis; for example, to detect the presence of parasites such as pinworms and their eggs (ova) or to detect disease-spreading bacteria. A stool culture—the controlled growth of microbial organisms in culture media under laboratory conditions—sometimes is performed to identify specific pathogens in stool. The stool guaiac test (or guaiac fecal occult blood test) is conducted to detect the presence of blood in stool that is not apparent to the unaided eye. The main pathogens that are commonly looked for in feces include:
Antimicrobial peptides are a unique and diverse group of molecules, which are divided into subgroups on the basis of their amino acid composition and structure. Antimicrobial peptides are generally between 12 and 50 amino acids. These peptides include two or more positively charged residues provided by arginine, lysine or, in acidic environments, histidine, and a large proportion (generally >50%) of hydrophobic residues. The secondary structures of these molecules follow 4 themes, including i) α-helical, ii) β-stranded due to the presence of 2 or more disulfide bonds, iii) β-hairpin or loop due to the presence of a single disulfide bond and/or cyclization of the peptide chain, and iv) extended. Many of these peptides are unstructured in free solution, and fold into their final configuration upon partitioning into biological membranes. The peptides contain hydrophilic amino acid residues aligned along one side and hydrophobic amino acid residues aligned along the opposite side of a helical molecule. This amphipathicity of the antimicrobial peptides allows them to partition into the membrane lipid bilayer. The ability to associate with membranes is a definitive feature of antimicrobial peptides, although membrane permeabilization is not necessary. These peptides have a variety of antimicrobial activities ranging from membrane permeabilization to action on a range of cytoplasmic targets.
Sources: en.wikipedia.org
It is a synthetic peptide analogue of growth hormone-releasing hormone. Four substitutions in its sequence make it more resistant to enzymatic degradation than the natural hormone. In the version carrying a drug affinity complex, the peptide binds albumin and remains in circulation for days.
No regulatory agency has approved CJC-1295 for clinical use. Human trials were conducted in the 2000s, but the development programme was discontinued before any marketing application succeeded. Material sold today is offered as a research chemical, and its purity depends on the supplier.
Sermorelin is an unmodified fragment of growth hormone-releasing hormone and is cleared quickly. CJC-1295 contains substitutions that resist breakdown, and the form with a drug affinity complex persists much longer. Both act at the same receptor but differ substantially in duration of action.
Natural GHRH is degraded quickly by dipeptidyl peptidase-4 and related enzymes, giving it a half-life measured in minutes. CJC-1295 carries substitutions that slow that breakdown, so it stays intact longer. Both act at the same pituitary receptor and produce the same class of signal.